FiftyBidsGovernment contracts and grants, in one plain-English search.

Back to search

Forecast

HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)

This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award to support milestone-driven research that advances innovative HIV prevention interventions from development and feasibility testing to larger-scale efficacy, effectiveness, implementation, and dissemination studies.

FromNational Institutes of Health
Who can applystate governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notesOther Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations.
How muchAmount not stated
DeadlineTue, Sep 7, 2027 (estimated) (318 days left)
CategoryHealth
TypeGrant
Opportunity #PAS-28-073
Assistance listing93.273
PostedThu, Oct 1, 2026

Heads-up: Forecast: not open yet. Dates and amounts are the agency's estimates.

Open the official posting

From the notice

This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award to support milestone-driven research that advances innovative HIV prevention interventions from development and feasibility testing to larger-scale efficacy, effectiveness, implementation, and dissemination studies. The R61 phase will support the development, refinement, adaptation, and pilot testing of novel or enhanced HIV prevention and treatment strategies, including studies designed to address key scientific, operational, or implementation questions necessary to establish feasibility and readiness for larger-scale evaluation. Projects may generate evidence needed to optimize intervention design, delivery, and implementation in diverse populations and settings. The R33 phase will support expanded testing of interventions and implementation strategies that have successfully met R61 milestones. Studies may evaluate effectiveness, implementation, scalability, sustainability, clinical management, or delivery of HIV prevention interventions that include integrated approaches addressing alcohol use and related comorbidities.

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.